Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $47,377.15 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,335 shares of the stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $20.29, for a total value of $47,377.15. Following the transaction, the insider now owns 166,809 shares in the company, valued at $3,384,554.61. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, July 9th, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.28, for a total value of $47,353.80.
• On Thursday, May 30th, Soleil Boughton sold 129,667 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.55, for a total value of $2,664,656.85.
• On Tuesday, May 28th, Soleil Boughton sold 2,502 shares of Hims & Hers Health stock. The stock was sold at an average price of $17.33, for a total value of $43,359.66.
• On Monday, May 20th, Soleil Boughton sold 4,915 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.01, for a total value of $98,349.15.
• On Monday, May 13th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The stock was sold at an average price of $12.33, for a total value of $30,861.99.
• On Monday, April 29th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The stock was sold at an average price of $12.56, for a total value of $31,437.68.

Hims & Hers Health Stock Down 6.4 %

Hims & Hers Health stock opened at $21.77 on Friday. Hims & Hers Health, Inc. has a one year low of $5.65 and a one year high of $25.74. The business has a fifty day moving average price of $21.07 and a 200-day moving average price of $15.28.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The firm had revenue of $278.20 million during the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same period last year, the company earned ($0.05) earnings per share. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on HIMS shares. Canaccord Genuity Group started coverage on Hims & Hers Health in a research note on Wednesday, April 10th. They set a “buy” rating and a $20.00 price target on the stock. Truist Financial increased their price objective on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Seaport Res Ptn reissued a “buy” rating on shares of Hims & Hers Health in a research note on Friday, April 26th. Citigroup downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $16.00 to $20.00 in a research note on Wednesday, May 22nd. Finally, Bank of America increased their price target on Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. Seven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $19.07.

Institutional Investors Weigh In On Hims & Hers Health

Several large investors have recently added to or reduced their stakes in HIMS. Allspring Global Investments Holdings LLC raised its position in Hims & Hers Health by 322.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 52,312 shares of the company’s stock valued at $1,056,000 after purchasing an additional 39,943 shares in the last quarter. State of Michigan Retirement System increased its holdings in shares of Hims & Hers Health by 177.8% in the second quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock worth $10,095,000 after buying an additional 320,000 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Hims & Hers Health by 67.5% in the second quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock worth $13,701,000 after buying an additional 273,473 shares during the period. Legacy Capital Group California Inc. purchased a new position in shares of Hims & Hers Health in the second quarter worth about $1,699,000. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after buying an additional 1,603 shares during the period. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.